Regioselectivity of CYP2B6: homology modeling, molecular dynamics simulation, docking

被引:28
|
作者
Bathelt, C [1 ]
Schmid, RD [1 ]
Pleiss, J [1 ]
机构
[1] Univ Stuttgart, Inst Tech Biochem, D-70569 Stuttgart, Germany
关键词
loop; MD simulation; P450; monooxygenase;
D O I
10.1007/s00894-002-0104-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human cytochrome P450 (CYP) 2B6 activates the anticancer prodrug cyclophosphamide (CPA) by 4-hydroxylation. In contrast, the same enzyme catalyzes N-deethylation of a structural isomer, the prodrug ifosfamide (IFA), thus causing severe adverse drug effects. To model the molecular interactions leading to a switch in regioselectivity, the structure of CYP2B6 was modeled based on the structure of rabbit CYP2C5. We modeled the missing 22-residue loop in CYP2C5 between helices F and G (the F G loop), which is not resolved in the Xray structure, by molecular dynamics (MD) simulations using a simulated annealing protocol. The modeled conformation of the loop was validated by unconstrained MD simulations of the complete enzymes (CYP2C5 and CYP2B6) in water for 70 and 120 ps, respectively. The simulations were stable and led to a backbone r.m.s. deviation of 1.7 Angstrom between the two CYPs. The shape of the substrate binding site of CYP2B6 was further analyzed. It consists of three well-defined hydrophobic binding pockets adjacent to the catalytic heme. Size, shape and hydrophobicity of these pockets were compared to the shapes of the two structurally isomeric substrates. In their preferred orientation in the binding site, both substrates fill all three binding pockets without repulsive interactions. The distance to the heme iron is short enough for 4-hydroxylation and N-deethylation to occur for CPA and IFA, respectively. However, if the substrates are docked in the non-preferred orientation (such that 4-hydroxylation and N-deethylation would occur for IFA and CPA, respectively), one pocket is left empty, and clashes were observed between the substrates and the enzyme. Electronic supplementary material to this paper can be obtained by using the Springer Link server located at http://dx.doi.org/10.1007/s00894-002-0104-y.
引用
收藏
页码:327 / 335
页数:9
相关论文
共 50 条
  • [21] Design and Screening of KLHL22 Inhibitors by Homology Modeling, Molecular Docking, and Molecular Dynamics Simulation
    Gao, Chenglong
    Sun, Chuance
    Zhang, Lichuan
    Zhang, Haoran
    Yu, Rilei
    Kang, Congmin
    [J]. LETTERS IN DRUG DESIGN & DISCOVERY, 2023, 20 (03) : 291 - 303
  • [22] CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function
    Mango, Katalin
    Kiss, Adam Ferenc
    Fekete, Ferenc
    Erdos, Reka
    Monostory, Katalin
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [23] CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function
    Katalin Mangó
    Ádám Ferenc Kiss
    Ferenc Fekete
    Réka Erdős
    Katalin Monostory
    [J]. Scientific Reports, 12
  • [24] A comparative analysis of binding sites between mouse CYP2C38 and CYP2C39 based on homology modeling, molecular dynamics simulation and docking studies
    Meng, Xuan-Yu
    Zheng, Qing-Chuan
    Zhang, Hong-Xing
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2009, 1794 (07): : 1066 - 1072
  • [25] Bioactivation of chlorpyrifos by CYP2B6 variants
    Crane, Alice L.
    Klein, Kathrin
    Olson, James R.
    [J]. XENOBIOTICA, 2012, 42 (12) : 1255 - 1262
  • [26] MEDI 50-Homology modeling and molecular dynamics simulation of Hepatitis B virus DNA polymerase: Validation using molecular docking
    Daga, Pankaj R.
    Doerksen, Robert J.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 235
  • [27] Haplotypes frequencies of CYP2B6 in Malaysia
    Musa, N.
    Zulkafli, M., I
    Talib, N.
    Mohamad, N.
    Fauzi, H.
    Ismail, R.
    [J]. JOURNAL OF POSTGRADUATE MEDICINE, 2012, 58 (04) : 235 - 241
  • [28] CYP2B6 GENETIC VARIATION AND EFAVIRENZ AUTOINDUCTION INFLUENCES CYP2B6 A ACTIVITY AND EFAVIRENZ EXPOSURE IN HEALTHY VOLUNTEERS
    Metzger, I. F.
    Lu, J. B.
    Kreutz, Y.
    Thong, N.
    Flockhart, D. A.
    Desta, Z.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S80 - S80
  • [29] In Silico Study of Desmosdumotin as an Anticancer Agent: Homology Modeling, Docking and Molecular Dynamics Simulation Approach
    Gadhe, Changdev G.
    Kothandan, Gugan
    Cho, Seung Joo
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (10) : 1636 - 1644
  • [30] Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics
    Saiz-Rodriguez, Miriam
    Ochoa, Dolores
    Roman, Manuel
    Zubiaur, Pablo
    Koller, Dora
    Mejia, Gina
    Abad-Santos, Francisco
    [J]. PHARMACOGENOMICS, 2020, 21 (10) : 663 - 675